Osteoprotegerin: A Promising Biomarker in the Metabolic Syndrome - New Perspectives
Carmen Perez de Ciriza Villacampa*
Laboratorio Pasteur, Clinical Biochemistry Department, Andorra la Vella, Andorra
- *Corresponding Author:
- Carmen Perez de Ciriza Villacampa
Laboratorio Pasteur, Clinical Biochemistry
Department, Andorra la Vella, Andorra
Email: [email protected]
Received date: June 20, 2016; Accepted date: September 12, 2016; Published date: September 15, 2016
Citation: Villacampa CPC (2016) Osteoprotegerin: A Promising Biomarker in the Metabolic Syndrome - New Perspectives. Biochem Anal Biochem 5:289. doi:10.4172/2161-1009.1000289
Copyright: © 2016 Villacampa CPC. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The metabolic syndrome (MS) is a cluster of cardio-metabolic alterations that has been known to increase the cardiovascular risk in these patients. The pathophysiological mechanisms underlying this observation remain unclear. In this context, osteoprotegerin (OPG) has emerged as a possible mechanism. The implication of OPG in cardiovascular disease and cardiovascular risk, the expression of this cytokine in different cells involved in the atheroma and the increased circulating concentration observed in these patients reinforce the hypothesis. In this manuscript, the clinical, the analytical and the cellular fields are studied in order to offer a wide perspective over the subject.